Her lab studies grasshopper mice that shrug off bark scorpion stings. OU has filed a patent, and Rowe has applied for NIH funding to start lab testing her peptide variants.
Recap by typeshit. Full story at The University of Oklahoma.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Grasshopper mice use a venom peptide to block pain outside the brain. Rowe's lab is reworking it with AlphaFold, and OU has filed a patent application.
Ashlee Rowe studies grasshopper mice that shrug off bark scorpion stings. OU has filed a patent on her redesigned peptides, which are not yet tested.
Loading…